{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-283719","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.409931+00:00","generated_at":"2026-06-07T21:06:04.581242+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phathom launches VOQUEZNA for erosive GERD; H. pylori regimens expected mid-Dec.","bullets":["VOQUEZNA (vonoprazan) now available in 30-count bottles for erosive GERD treatment and heartburn relief.","Phase 3 trial: 93% healing rate at Week 8 with VOQUEZNA 20mg vs 85% for lansoprazole 30mg.","VOQUEZNA 10mg superior to lansoprazole 15mg at maintaining healing at 6 months (79% vs 72%).","No mealtime dosing required; prescriptions fillable at major retail pharmacies and via BlinkRx.","VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori expected commercially by mid-December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-283719","json":"https://secwatch.observer/filing/0001193125-23-283719.json","markdown":"https://secwatch.observer/filing/0001193125-23-283719.md","text":"https://secwatch.observer/filing/0001193125-23-283719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523283719/0001193125-23-283719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523283719/d573061d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:06:04.581242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}